VALENCIA, Calif., June 15 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) announced today that it has reached a final resolution in the civil litigation filed by its former Chief Medical Officer, Dr. Wayman Wendell Cheatham.

Dr. Cheatham filed a Complaint in May 2005, alleging causes of action for wrongful termination in violation of public policy and breach of contract, following the termination of Dr. Cheatham's employment on May 2, 2005. A trial on these matters began on April 30, 2007 and concluded on June 5, 2007. In connection with the resolution of the litigation, Dr. Cheatham stated, "The Complaint and allegations have been dismissed. I have confidence in MannKind Corporation and its Technosphere(R) Insulin product."

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.

SOURCE MannKind Corporation

CONTACT:
David Thomson,
General Counsel of MannKind Corporation,
+1-661-775-5350,
dthomson@mannkindcorp.com;
or
Investors,Evan Smith
of Financial Dynamics,
+1-212-850-5606,
mnkd@fd.com,
for MannKind Corporation

Web site: http://www.mannkindcorp.com